Pharmacokinetics and Safety Study of Levornidazole Disodium Phosphate for Injection in Subjects With Renal Impairment and Normal Renal Impairment
NCT ID: NCT07033182
Last Updated: 2025-06-24
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
24 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-10-30
Study Completion Date
2024-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To evaluate the pharmacokinetics and safety of a single intravenous dose of levornidazole disodium phosphate for injection in subjects with moderate and severe renal impairment and healthy subjects.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function
NCT06657560
Contrast-Enhanced Magnetic Resonance Imaging Detection
COMPLETED
PHASE1
A Safety, PK, PD and Food Effect Study of URC102 in Healthy Adults and Patients With Renal Impairment
NCT05198778
Healthy, Renal Impairment
COMPLETED
PHASE1
Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients
NCT05116826
Moderate Hepatic Impairment
Severe Hepatic Impairment
Liver Diseases
COMPLETED
PHASE1
A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment
NCT07104162
Bacterial Infections
RECRUITING
PHASE1
Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Single Dose Lacosamide in Subjects With Renal Impairment Compared to Healthy Subjects
NCT01796938
Healthy
Renal Impairment
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Infections Caused by Anaerobic Bacteria
Renal Impairment
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental Group A
Severe renal impairment
Group Type
EXPERIMENTAL
Levornidazole Disodium Phosphate for Injection
Intervention Type
DRUG
Single dose, IV
Experimental Group B
Moderate renal impairment
Group Type
EXPERIMENTAL
Levornidazole Disodium Phosphate for Injection
Intervention Type
DRUG
Single dose, IV
Experimental Group C
Normal renal function
Group Type
EXPERIMENTAL
Levornidazole Disodium Phosphate for Injection
Intervention Type
DRUG
Single dose, IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levornidazole Disodium Phosphate for Injection
Single dose, IV
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
\-
1. Subjects who are able to understand and willing to complete the study in strict compliance with the clinical protocol and sign the informed consent form.
2. Male or female subjects aged 18-75 years (inclusive).
3. Weight ≥ 50.0 kg for males, or ≥ 45.0 kg for females, and body mass index (BMI) in the range of 19.0 \~ 30.0 kg/m2 (inclusive).
4. Subjects with diagnosis of chronic kidney disease and/or absolute eGFR did not change significantly within 1 month before screening, absolute eGFR met the renal function classification criteria in the corresponding group at screening, severe renal insufficiency, absolute eGFR: 15 \~ 29 mL/min; moderate renal insufficiency, absolute eGFR: 30 \~ 59 mL/min.
5. Subjects of childbearing potential (including partners), voluntarily take appropriate contraceptive measures from 2 weeks before screening to 3 months after dosing.
1. Subjects who are able to understand and willing to complete the study in strict compliance with the clinical protocol and sign the informed consent form.
2. Male and female subjects aged 18 - 75 years (inclusive) were matched with subjects in groups A and B for age (mean ± 10 years) and gender (mean ± 1 case of gender in groups A and B).
3. Weight ≥ 50.0 kg for males, or ≥ 45.0 kg for females, and body mass index (BMI) in the range of 19.0 \~ 30.0 kg/m2, matched with BMI of subjects in groups A and B(mean ± 15%).
4. Normal renal function, 90 mL/min ≤ absolute eGFR \< 130 mL/min.
5. Screening physical examination, vital signs, 12-lead electrocardiogram, laboratory tests, imaging and abdominal ultrasonography results were normal or abnormal but the investigator judged no clinical significance.
6. Subjects of childbearing potential (including partners), voluntarily take appropriate contraceptive measures from 2 weeks before screening to 3 months after dosing.
1. Subjects who are able to understand and willing to complete the study in strict compliance with the clinical protocol and sign the informed consent form.
2. Male or female subjects aged 18-75 years (inclusive).
3. Weight ≥ 50.0 kg for males, or ≥ 45.0 kg for females, and body mass index (BMI) in the range of 19.0 \~ 30.0 kg/m2 (inclusive).
4. Subjects with diagnosis of chronic kidney disease and/or absolute eGFR did not change significantly within 1 month before screening, absolute eGFR met the renal function classification criteria in the corresponding group at screening, severe renal insufficiency, absolute eGFR: 15 \~ 29 mL/min; moderate renal insufficiency, absolute eGFR: 30 \~ 59 mL/min.
5. Subjects of childbearing potential (including partners), voluntarily take appropriate contraceptive measures from 2 weeks before screening to 3 months after dosing.
1. Subjects who are able to understand and willing to complete the study in strict compliance with the clinical protocol and sign the informed consent form.
2. Male and female subjects aged 18 - 75 years (inclusive) were matched with subjects in groups A and B for age (mean ± 10 years) and gender (mean ± 1 case of gender in groups A and B).
3. Weight ≥ 50.0 kg for males, or ≥ 45.0 kg for females, and body mass index (BMI) in the range of 19.0 \~ 30.0 kg/m2, matched with BMI of subjects in groups A and B(mean ± 15%).
4. Normal renal function, 90 mL/min ≤ absolute eGFR \< 130 mL/min.
5. Screening physical examination, vital signs, 12-lead electrocardiogram, laboratory tests, imaging and abdominal ultrasonography results were normal or abnormal but the investigator judged no clinical significance.
6. Subjects of childbearing potential (including partners), voluntarily take appropriate contraceptive measures from 2 weeks before screening to 3 months after dosing.
Exclusion Criteria
\-
1. Subjects who are known to be allergic to levornidazole phosphate disodium, levornidazole, ornidazole, other nitroimidazoles or their excipients, or have a history of drug or food allergy, or have a history of specific allergic diseases (such as asthma, urticaria, eczema, etc.).
2. Subjects who have special dietary requirements,who cannot accept a unified diet.
3. Subjects who have poor peripheral venous access or cannot tolerate venous puncture or have a history of needle and blood fainting.
4. Subjects who have received renal transplantation and/or require renal dialysis during the study.
5. Subjects combined with cardiovascular, respiratory, digestive, endocrine, malignant tumor, hematopoietic, mental/nervous system serious diseases in addition to the disease causing renal dysfunction itself, which are considered not suitable for participation by the investigator.
6. Subjects with other clinically significant abnormalities except for laboratory tests, physical examination, vital signs, 12-lead electrocardiogram, imaging tests, and abdominal ultrasonography that are judged to be caused by renal insufficiency and its associated diseases, such as ALT (alanine aminotransferase) and/or AST (aspartate aminotransferase) \> 2 times the upper limit of normal and/or TBIL (total bilirubin) \> 1.5 times the upper limit of normal; Hb (hemoglobin) \< 80 g/L; QTc \> 450 ms in men and QTc \> 470 ms in women.
7. Subjects with poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg) or heart rate \> 120 bmp.
8. Patients with diabetic nephropathy HbAlc (glycosylated hemoglobin) \> 8.5% or fasting blood glucose \> 8.5 mmol/L, or stable treatment regimen for less than 1 month before screening.
9. Subjects with clinically significant abnormalities in any of hepatitis B virus surface antigen, Treponema pallidum-specific antibody, human immunodeficiency virus antibody, hepatitis C virus antibody.
10. Subjects with a history of drug abuse, drug use within 6 months before screening, or positive drug abuse screening.
11. Subjects who frequently consume alcohol within 3 months prior to screening, i.e., consuming more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% spirits, or 150 mL of wine), or who cannot stop using any alcohol products during the study, or alcohol breath test result \> 0.0 mg/100 mL.
12. Subjects who have donated blood or experienced massive blood loss (\> 400 mL) within 3 months prior to screening, received blood transfusions or used blood products, planned to donate blood during the trial period or within 1 month after the end of the trial.
13. Subjects who have consumed excessive tea, coffee and/or caffeine-containing beverages (more than 8 cups, 1 cup ≈ 250 mL) daily during the 3 months before screening.
14. Subjects smoke an average of 5 or more cigarettes per day within 3 months prior to screening, or those who cannot stop using any tobacco products during the study.
15. Subjects who have participated in any clinical trial within 3 months prior to screening, or plan to participate in other clinical trials during the study.
16. Subjects who have received any surgery or severe trauma that may affect the safety of the trial or the process of drug in vivo within 30 days before screening, or plan to undergo surgery during the study.
17. Subjects who have received vaccination within 30 days prior to screening, or plan to receive vaccination during the study.
18. Subjects who have used any drugs that inhibit or induce hepatic metabolism of drugs within 30 days before administration.
19. Subjects who have used any prescription drugs, over-the-counter drugs, vitamin products, health products or Chinese herbal medicines other than those for the treatment of renal insufficiency and or its concomitant chronic diseases within 14 days before administration.
20. Subjects who started taking new drugs, dosage forms or adjusted current doses for the treatment of chronic kidney disease and its combined chronic diseases within 14 days before administration.
21. Subjects who have consumed grapefruit, pomelo, pitaya, mango and other fruits or related products affecting metabolic enzymes within 7 days before administration.
22. Subjects who have consumed xanthine-rich, caffeine-containing or alcohol-containing beverages or foods (such as animal viscera, coffee, strong tea, chocolate, cola, etc.) within 48 hours before administration.
23. Lactating women, or women who test positive for pregnancy.
24. Subjects with acute illness from screening to prior to administration.
25. Those who, in the opinion of the investigator, are not suitable for inclusion.
1. Subjects who are known to be allergic to levornidazole phosphate disodium, levornidazole, ornidazole, other nitroimidazoles or their excipients, or have a history of drug or food allergy, or have a history of specific allergic diseases (such as asthma, urticaria, eczema, etc.).
2. Subjects who have special dietary requirements,who cannot accept a unified diet.
3. Subjects who have poor peripheral venous access or cannot tolerate venous puncture or have a history of needle and blood fainting.
4. Subjects who have a history of serious diseases and chronic diseases such as respiratory system, circulatory system, digestive system, urinary system, blood system, endocrine system, immune system, nervous system, mental system.
5. Those who are positive in any index screening of hepatitis B virus surface antigen, Treponema pallidum-specific antibody, human immunodeficiency virus antibody,or hepatitis C virus antibody；
6. Subjects with a history of drug abuse, drug use within 6 months before screening, or positive drug abuse screening;
7. Subjects who frequently consume alcohol within 3 months prior to screening, i.e., consuming more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% spirits, alcohol or 150 mL of wine), or who cannot stop using any alcohol products during the study, or whose alcohol breath test result \> 0.0 mg/100 mL;
8. Subjects who have donated blood or experienced massive blood loss (\> 400 mL) within 3 months prior to screening, received blood transfusions or used blood products, planned to donate blood during the trial period or within 1 month after the end of the trial;
9. Subjects who have consumed excessive tea, coffee and/or caffeine-containing beverages (more than 8 cups, 1 cup ≈ 250 mL) daily during the 3 months before screening;
10. Subjects smoke an average of 5 or more cigarettes per day within 3 months prior to screening, or those who cannot stop using any tobacco products during the study.
11. Subjects who have participated in any clinical trial within 3 months prior to screening, or plan to participate in other clinical trials during the study.
12. Subjects who have received any surgery or severe trauma that may affect the safety of the trial or the process of drug in vivo within 30 days before screening, or plan to undergo surgery during the study.
13. Subjects who have received vaccination within 30 days prior to screening, or plan to receive vaccination during the study.
14. Subjects who have used any drugs that inhibit or induce hepatic metabolism of drugs within 30 days before administration.
15. Subjects who have taken any prescription drugs, over-the-counter drugs, health products, vitamins, and Chinese herbal medicines within 14 days before administration.
16. Subjects who have consumed grapefruit, pomelo, pitaya, mango and other fruits or related products affecting metabolic enzymes within 7 days before administration.
17. Subjects who have consumed xanthine-rich, caffeine-containing or alcohol-containing beverages or foods (such as animal viscera, coffee, strong tea, chocolate, cola, etc.) within 48 hours before administration.
18. Lactating women, or women who test positive for pregnancy.
19. Subjects with acute illness from screening to prior to administration.
20. Those who, in the opinion of the investigator, are not suitable for inclusion.
1. Subjects who are known to be allergic to levornidazole phosphate disodium, levornidazole, ornidazole, other nitroimidazoles or their excipients, or have a history of drug or food allergy, or have a history of specific allergic diseases (such as asthma, urticaria, eczema, etc.).
2. Subjects who have special dietary requirements,who cannot accept a unified diet.
3. Subjects who have poor peripheral venous access or cannot tolerate venous puncture or have a history of needle and blood fainting.
4. Subjects who have received renal transplantation and/or require renal dialysis during the study.
5. Subjects combined with cardiovascular, respiratory, digestive, endocrine, malignant tumor, hematopoietic, mental/nervous system serious diseases in addition to the disease causing renal dysfunction itself, which are considered not suitable for participation by the investigator.
6. Subjects with other clinically significant abnormalities except for laboratory tests, physical examination, vital signs, 12-lead electrocardiogram, imaging tests, and abdominal ultrasonography that are judged to be caused by renal insufficiency and its associated diseases, such as ALT (alanine aminotransferase) and/or AST (aspartate aminotransferase) \> 2 times the upper limit of normal and/or TBIL (total bilirubin) \> 1.5 times the upper limit of normal; Hb (hemoglobin) \< 80 g/L; QTc \> 450 ms in men and QTc \> 470 ms in women.
7. Subjects with poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg) or heart rate \> 120 bmp.
8. Patients with diabetic nephropathy HbAlc (glycosylated hemoglobin) \> 8.5% or fasting blood glucose \> 8.5 mmol/L, or stable treatment regimen for less than 1 month before screening.
9. Subjects with clinically significant abnormalities in any of hepatitis B virus surface antigen, Treponema pallidum-specific antibody, human immunodeficiency virus antibody, hepatitis C virus antibody.
10. Subjects with a history of drug abuse, drug use within 6 months before screening, or positive drug abuse screening.
11. Subjects who frequently consume alcohol within 3 months prior to screening, i.e., consuming more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% spirits, or 150 mL of wine), or who cannot stop using any alcohol products during the study, or alcohol breath test result \> 0.0 mg/100 mL.
12. Subjects who have donated blood or experienced massive blood loss (\> 400 mL) within 3 months prior to screening, received blood transfusions or used blood products, planned to donate blood during the trial period or within 1 month after the end of the trial.
13. Subjects who have consumed excessive tea, coffee and/or caffeine-containing beverages (more than 8 cups, 1 cup ≈ 250 mL) daily during the 3 months before screening.
14. Subjects smoke an average of 5 or more cigarettes per day within 3 months prior to screening, or those who cannot stop using any tobacco products during the study.
15. Subjects who have participated in any clinical trial within 3 months prior to screening, or plan to participate in other clinical trials during the study.
16. Subjects who have received any surgery or severe trauma that may affect the safety of the trial or the process of drug in vivo within 30 days before screening, or plan to undergo surgery during the study.
17. Subjects who have received vaccination within 30 days prior to screening, or plan to receive vaccination during the study.
18. Subjects who have used any drugs that inhibit or induce hepatic metabolism of drugs within 30 days before administration.
19. Subjects who have used any prescription drugs, over-the-counter drugs, vitamin products, health products or Chinese herbal medicines other than those for the treatment of renal insufficiency and or its concomitant chronic diseases within 14 days before administration.
20. Subjects who started taking new drugs, dosage forms or adjusted current doses for the treatment of chronic kidney disease and its combined chronic diseases within 14 days before administration.
21. Subjects who have consumed grapefruit, pomelo, pitaya, mango and other fruits or related products affecting metabolic enzymes within 7 days before administration.
22. Subjects who have consumed xanthine-rich, caffeine-containing or alcohol-containing beverages or foods (such as animal viscera, coffee, strong tea, chocolate, cola, etc.) within 48 hours before administration.
23. Lactating women, or women who test positive for pregnancy.
24. Subjects with acute illness from screening to prior to administration.
25. Those who, in the opinion of the investigator, are not suitable for inclusion.
1. Subjects who are known to be allergic to levornidazole phosphate disodium, levornidazole, ornidazole, other nitroimidazoles or their excipients, or have a history of drug or food allergy, or have a history of specific allergic diseases (such as asthma, urticaria, eczema, etc.).
2. Subjects who have special dietary requirements,who cannot accept a unified diet.
3. Subjects who have poor peripheral venous access or cannot tolerate venous puncture or have a history of needle and blood fainting.
4. Subjects who have a history of serious diseases and chronic diseases such as respiratory system, circulatory system, digestive system, urinary system, blood system, endocrine system, immune system, nervous system, mental system.
5. Those who are positive in any index screening of hepatitis B virus surface antigen, Treponema pallidum-specific antibody, human immunodeficiency virus antibody,or hepatitis C virus antibody；
6. Subjects with a history of drug abuse, drug use within 6 months before screening, or positive drug abuse screening;
7. Subjects who frequently consume alcohol within 3 months prior to screening, i.e., consuming more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% spirits, alcohol or 150 mL of wine), or who cannot stop using any alcohol products during the study, or whose alcohol breath test result \> 0.0 mg/100 mL;
8. Subjects who have donated blood or experienced massive blood loss (\> 400 mL) within 3 months prior to screening, received blood transfusions or used blood products, planned to donate blood during the trial period or within 1 month after the end of the trial;
9. Subjects who have consumed excessive tea, coffee and/or caffeine-containing beverages (more than 8 cups, 1 cup ≈ 250 mL) daily during the 3 months before screening;
10. Subjects smoke an average of 5 or more cigarettes per day within 3 months prior to screening, or those who cannot stop using any tobacco products during the study.
11. Subjects who have participated in any clinical trial within 3 months prior to screening, or plan to participate in other clinical trials during the study.
12. Subjects who have received any surgery or severe trauma that may affect the safety of the trial or the process of drug in vivo within 30 days before screening, or plan to undergo surgery during the study.
13. Subjects who have received vaccination within 30 days prior to screening, or plan to receive vaccination during the study.
14. Subjects who have used any drugs that inhibit or induce hepatic metabolism of drugs within 30 days before administration.
15. Subjects who have taken any prescription drugs, over-the-counter drugs, health products, vitamins, and Chinese herbal medicines within 14 days before administration.
16. Subjects who have consumed grapefruit, pomelo, pitaya, mango and other fruits or related products affecting metabolic enzymes within 7 days before administration.
17. Subjects who have consumed xanthine-rich, caffeine-containing or alcohol-containing beverages or foods (such as animal viscera, coffee, strong tea, chocolate, cola, etc.) within 48 hours before administration.
18. Lactating women, or women who test positive for pregnancy.
19. Subjects with acute illness from screening to prior to administration.
20. Those who, in the opinion of the investigator, are not suitable for inclusion.
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Affiliated Hospital of Zhengzhou University
OTHER
Sponsor Role
collaborator
Beijing Haisha Consulting Co., Ltd
UNKNOWN
Sponsor Role
collaborator
Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, , China
Site Status
Countries
Review the countries where the study has at least one active or historical site.
China
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YZJ-ZAXZ-403
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Pharmacokinetics of LCQ908 in Patients With Renal Impairment
NCT01558323
COMPLETED
PHASE1
Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir
NCT05731804
UNKNOWN
PHASE1
Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects
NCT05368935
COMPLETED
PHASE1
A Study to Evaluate the Pharmacokinetics of HSK16149 in Subjects With Renal Impairment
NCT05916573
COMPLETED
PHASE1
Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function
NCT02729038
COMPLETED
PHASE1
Pharmacokinetics of Benapenem in Subjects With Renal Impairment
NCT04476407
COMPLETED
PHASE1
Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011
NCT02431481
COMPLETED
PHASE1
Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment vs. Matched Healthy Subjects With Normal Renal Function
NCT01569828
COMPLETED
PHASE2
Phase 1 Study in Healthy Participants and Participants With Kidney Dysfunction
NCT06383897
NOT_YET_RECRUITING
PHASE1
A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions
NCT06357910
COMPLETED
PHASE1
Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment
NCT04469907
COMPLETED
PHASE1
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers
NCT04611932
UNKNOWN
PHASE1
A Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult Subjects
NCT07027982
COMPLETED
PHASE1
A Study on the Effect of Renal Impairment on the Pharmacokinetics of RO4917838
NCT01510899
COMPLETED
PHASE1
A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function
NCT06402721
COMPLETED
PHASE1
Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment
NCT01763190
COMPLETED
PHASE1
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment
NCT03289208
COMPLETED
PHASE1
Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment
NCT05086107
COMPLETED
PHASE1
Pharmacokinetics of BF2.649 in Renal Impairment
NCT01619033
COMPLETED
PHASE1
Safety, Tolerability, and Pharmacokinetic of Single Dose of Pitavastatin 4 mg in Severe Renal Patients Versus Healthy Adult Volunteers
NCT01043094
COMPLETED
PHASE4
Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)
NCT05093972
NOT_YET_RECRUITING
PHASE1
Single-dose Pharmacokinetics and Safety of Oral Lofexidine in Renally-Impaired Subjects
NCT02313103
COMPLETED
PHASE1
Multiple-dose Tolerability and Pharmacokinetic Studies of Benapenem in Clinical Healthy Subjects
NCT04200261
UNKNOWN
PHASE1
Multiple-dose Tolerability and Pharmacokinetic Studies of Benapenem inClinical Healthy Subjects
NCT03570970
COMPLETED
PHASE1